首页> 外文期刊>Advanced Biomedical Research >Pseudomonas aeruginosa-producing Metallo-β-lactamases (VIM, IMP, SME, and AIM) in the Clinical Isolates of Intensive Care Units, a University Hospital in Isfahan, Iran
【24h】

Pseudomonas aeruginosa-producing Metallo-β-lactamases (VIM, IMP, SME, and AIM) in the Clinical Isolates of Intensive Care Units, a University Hospital in Isfahan, Iran

机译:伊朗伊斯法罕大学医院重症监护病房临床分离株中产生铜绿假单胞菌的Metallo-β-内酰胺酶(VIM,IMP,SME和AIM)

获取原文
           

摘要

Background: Pseudomonas aeruginosa is a severe challenge for antimicrobial therapy, due to the chromosomal mutations or exhibition of intrinsic resistance to various antimicrobial agents such as most β-lactams. We undertook this study to evaluate the existence of SME, IMP, AIM, and VIM metallo-β-lactamases (MBL) encoding genes among P. aeruginosa strains isolated from Intensive Care Unit (ICU) patients in Al-Zahra Hospital in Isfahan, Iran. Materials and Methods: In a retrospective cross-sectional study that was conducted between March 2012 and April 2013, a total of 48 strains of P. aeruginosa were collected from clinical specimens of bedridden patients in ICU wards. Susceptibility test was performed by disc diffusion method. All of the meropenem-resistant strains were subjected to modified Hodge test for detection of carbapenemases. Multiplex polymerase chain reaction was performed for detection of blaVIM, blaIMP, blaAIM, and blaSME genes. Results: In disk diffusion method, imipenem and meropenem showed the most and colistin the least resistant antimicrobial agents against P. aeruginosa strains. Of the 48 isolates, 36 (75%) were multidrug resistant (MDR). Amplification of β-lactamase genes showed the presence of blaVIM genes in 7 (%14.6) strains and blaIMP genes in 15 (31.3%) strains. All of the isolates were negative for blaSME and blaAIM genes. We could not find any statistically significant difference among the presence of this gene and MDR positive, age, or source of the specimen. Conclusion: As patients with infections caused by MBL-producing bacteria are at an intensified risk of treatment failure, fast determination of these organisms is necessary. Our findings may provide useful insights in replace of the appropriate antibiotics and may also prevent MBLs mediated resistance problem.
机译:背景:铜绿假单胞菌(Pseudomonas aeruginosa)是抗菌治疗的严峻挑战,因为其染色体突变或对多种抗菌剂(例如大多数β-内酰胺类)表现出内在抗性。我们进行了这项研究以评估伊朗伊斯法罕Al-Zahra医院重症监护病房(ICU)患者分离出的铜绿假单胞菌菌株中SME,IMP,AIM和VIM金属β-内酰胺酶(MBL)编码基因的存在。材料和方法:在2012年3月至2013年4月之间进行的一项回顾性横断面研究中,从ICU病床的卧床患者的临床标本中总共采集了48株铜绿假单胞菌菌株。药敏试验采用圆盘扩散法进行。所有耐美罗培南的菌株均经过改良的Hodge测试,用于检测碳青霉烯酶。进行多重聚合酶链反应以检测blaVIM,blaIMP,blaAIM和blaSME基因。结果:在圆盘扩散法中,亚胺培南和美罗培南对铜绿假单胞菌菌株的耐药性最高,而大肠粘菌素的耐药性最低。在48株分离物中,有36株(75%)具有多重耐药性(MDR)。 β-内酰胺酶基因的扩增显示在7(%14.6)株中存在blaVIM基因,在15(31.3%)株中存在blaIMP基因。所有分离株均为blaSME和blaAIM基因阴性。在该基因的存在与MDR阳性,年龄或样本来源之间,我们找不到任何统计学上的显着差异。结论:由于患有由MBL产生细菌引起的感染的患者面临更大的治疗失败风险,因此有必要对这些微生物进行快速测定。我们的发现可能为替代适当的抗生素提供有用的见解,也可以预防MBL介导的耐药性问题。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号